Molecular Stethoscope

The company is a small team and lists open positions.

The company invites researchers and therapeutics developers to partner on clinical trials and research using its diagnostic.

The page covers circulating RNA, tissue and organ health, cell-free RNA, and molecular diagnostics from Molecular Stethoscope.

Molecular Stethoscope reports that its cf-mRNA RNA-Seq and machine-learning platform was used in a mouse study profiling cell-free messenger RNA. The study maps systemic and organ-specific inflammatory responses and examines the effect of a JAK/STAT pathway inhibitor, using the platform to assess immune responses in circulating and solid-organ compartments for potential applications in pre-clinical and clinical drug development.

Sep 2022 · PR NewswireNews article

Molecular Stethoscope receives an investment from the Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation to advance its cf-mRNA liquid biopsy platform. The company is developing the platform toward clinical-grade products for diagnosing and managing Alzheimer's disease, building on a published human proof-of-concept study in Science Advances; ADDF describes blood-based biomarkers as promising for early, non-invasive detection.

Jun 2022 · CNW GroupNews article

Molecular Stethoscope relocates its corporate headquarters and R&D laboratories to South San Francisco, joining Verily Life Sciences’ partnered laboratory ecosystem, and appoints former Fluidigm chief executive Gajus Worthington as executive chairman of its board. The company says the move will accelerate translation of its cf-mRNA liquid biopsy platform, which has published human proof-of-concept studies in transplant oncology, Alzheimer’s disease, and liver disease.

Jan 2022 · PR NewswireNews article

Molecular Stethoscope raises $8.2 million in seed financing and enters a two-year research collaboration with Pfizer to develop a blood-based assay for cardiometabolic disease progression. The company says it will use the funding to advance liquid biopsy tests based on circulating cell-free RNA; the round includes DCVC, Pfizer, Index Ventures, and a leading U.S. research university.

Jan 2017 · PfizerNews article